Decorated of Au NPs over L-arginine-modified Fe3O4 nanoparticles as a novel nanomagnetic composite for the treatment of human ovarian cancer

In this study, an eco-friendly and low cost method for the fabrication of L-arginine modified magnetic nanocomposite (L-arginine/Fe3O4) has been demonstrated. Au nanoparticles (Au NPs) were further decorated over the designed L-arginine/Fe3O4 nanocomposite exploiting the sodium borohydride as reductant agent. The resulting Au NPs/L-arginine/Fe3O4 nanocomposite was characterized by various analytical methods like field emission scanning electron microscopy (FESEM), energy dispersive X-ray analysis (EDX), transmission electron microscopes (TEM), vibrating-sample magnetometer (VSM), X-ray diffraction (XRD) and inductively coupled plasma atomic emission spectroscopy (ICP-AES) analysis. In the antioxidant test, the IC50 of Au NPs/L-arginine/Fe3O4 nanocomposite and butylated hydroxytoluene (BHT) against 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radicals were 180 and 125 mu g/mL, respectively. In the cellular and molecular part of the recent study, the treated cells with Au NPs/L-arginine/Fe3O4 nanocomposite were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay for 48 h about the cytotoxicity and anti-human ovarian cancer properties on normal (Human umbilical vein endothelial cells (HUVECs)) and ovarian cancer cell lines i.e. SK-OV-3, SW-626, and PA-1. The IC50 of Au NPs/L-arginine/Fe3O4 nanocomposite were 213, 162, and 149 mu g/mL against PA-1, SW-626, and SK-OV-3 cell lines, respectively. The viability of malignant ovarian cell line reduced dose-dependently in the presence of Au NPs/L-arginine/Fe3O4 nanocomposite. It seems that the anti-human ovarian cancer effect of recent nanoparticles is due to their antioxidant effects. (C) 2021 Published by Elsevier B.V. on behalf of King Saud University.